HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 291/1/E175    most recent 00453.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (30) Citing Articles via Google Scholar Google Scholar Articles by LeBrasseur, N. K. Articles by Tomas, E. Search for Related Content PubMed PubMed Citation Articles by LeBrasseur, N. K. Articles by Tomas, E.

Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues

¹Diabetes and Metabolism Unit and ²Department of Biochemistry, Boston University School of Medicine, Boston; and ³Whitehead Institute for Biomedical Research, Cambridge, Massachusetts

Submitted 18 September 2005 ; accepted in final form 3 February 2006

Thiazolidinediones (TZDs) are insulin-sensitizing agents used in the treatment of type 2 diabetes. A widely held view is that their action is secondary to transcriptional events that occur when TZDs bind to the nuclear receptor PPAR in the adipocyte and stimulate adipogenesis. It has been proposed that this increases insulin sensitivity, at least in part, by increasing the expression and release of adiponectin, an adipokine that activates the fuel-sensing enzyme AMP-activated protein kinase (AMPK). In this study, we report that TZDs also acutely activate AMPK in skeletal muscle and other tissues by a mechanism that is likely independent of PPAR-regulated gene transcription. Thus incubation of isolated rat EDL muscles in medium containing 5 µM troglitazone for 15 min (too brief to be attributable to transcription) significantly increased pAMPK and pACC. At a concentration of 100 µM, troglitazone maximally increased these parameters and caused twofold increases in 2-deoxy-D-glucose uptake and the oxidation of exogenous [¹⁴C]palmitate. Time course studies revealed that troglitazone-induced increases in pAMPK and pACC abundance at 15 min were paralleled by an increase in the AMP-to-ATP ratio and that by 60 min all of these parameters had returned to baseline values. Increases in pAMPK and pACC were also observed in skeletal muscle, liver, and adipose tissue in intact rats 15 min after the administration of a single dose of troglitazone (10 mg/kg, ip). Likewise, troglitazone and another TZD, pioglitazone, caused rapid increases in pAMPK and pACC of equal magnitude in Swiss 3T3 fibroblasts with and without sufficient PPAR to mediate the expression of target genes. The results indicate that TZDs can act within minutes to activate AMPK in mammalian tissues. They suggest that this effect is associated with a change in cellular energy state and that it is not dependent on PPAR-mediated gene transcription.

acetyl-coenzyme A carboxylase; adiponectin; diabetes; insulin sensitivity; metabolism

This article has been cited by other articles:

				Z. Szocs, B. Brunmair, K. Stadlbauer, P. Nowotny, L. Bauer, A. Luger, and C. Furnsinn Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 323 - 329. [Abstract] [Full Text] [PDF]

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

				A. Lombardi, G. Cantini, E. Piscitelli, S. Gelmini, M. Francalanci, T. Mello, E. Ceni, G. Varano, G. Forti, M. Rotondi, et al. A New Mechanism Involving ERK Contributes to Rosiglitazone Inhibition of Tumor Necrosis Factor-{alpha} and Interferon-{gamma} Inflammatory Effects in Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 718 - 724. [Abstract] [Full Text] [PDF]

				G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al. Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2627 - 2633. [Abstract] [Full Text] [PDF]

				Z. Song, I. Deaciuc, Z. Zhou, M. Song, T. Chen, D. Hill, and C. J. McClain Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G894 - G902. [Abstract] [Full Text] [PDF]

				C. A. Stuart, M. E.A. Howell, and D. Yin Overexpression of GLUT5 in Diabetic Muscle Is Reversed by Pioglitazone Diabetes Care, April 1, 2007; 30(4): 925 - 931. [Abstract] [Full Text] [PDF]

				B. Askari, J. E. Kanter, A. M. Sherrid, D. L. Golej, A. T. Bender, J. Liu, W. A. Hsueh, J. A. Beavo, R. A. Coleman, and K. E. Bornfeldt Rosiglitazone Inhibits Acyl-CoA Synthetase Activity and Fatty Acid Partitioning to Diacylglycerol and Triacylglycerol via a Peroxisome Proliferator-Activated Receptor-{gamma}-Independent Mechanism in Human Arterial Smooth Muscle Cells and Macrophages Diabetes, April 1, 2007; 56(4): 1143 - 1152. [Abstract] [Full Text] [PDF]

				F. Turturro, R. Oliver III, E. Friday, I. Nissim, and T. Welbourne Troglitazone and pioglitazone interactions via PPAR-{gamma}-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1137 - C1146. [Abstract] [Full Text] [PDF]

				K. Wada, A. Nakajima, K. Katayama, C. Kudo, A. Shibuya, N. Kubota, Y. Terauchi, M. Tachibana, H. Miyoshi, Y. Kamisaki, et al. Peroxisome Proliferator-activated Receptor {gamma}-mediated Regulation of Neural Stem Cell Proliferation and Differentiation J. Biol. Chem., May 5, 2006; 281(18): 12673 - 12681. [Abstract] [Full Text] [PDF]